KR960703600A - PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF Download PDF

Info

Publication number
KR960703600A
KR960703600A KR1019960700363A KR19960700363A KR960703600A KR 960703600 A KR960703600 A KR 960703600A KR 1019960700363 A KR1019960700363 A KR 1019960700363A KR 19960700363 A KR19960700363 A KR 19960700363A KR 960703600 A KR960703600 A KR 960703600A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
represents hydrogen
formula
alkoxy
Prior art date
Application number
KR1019960700363A
Other languages
Korean (ko)
Inventor
노그라디 미할리
가트세건 아그네스
앤투스 산도르
스트렐리스키 자노스
베르메스 보르발라
울프네르 앤드라스
마조르 아담
스쥐츠 타마스
벤데피 이스트반네
마르마로시 타마스네
Original Assignee
지요르기 블라스코, 카탈린 마르마로시
키노인지오지체르 에스베기에스 체테르 메케크기애라알티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지요르기 블라스코, 카탈린 마르마로시, 키노인지오지체르 에스베기에스 체테르 메케크기애라알티 filed Critical 지요르기 블라스코, 카탈린 마르마로시
Publication of KR960703600A publication Critical patent/KR960703600A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 활성제로서 하기 일반식(Ⅰ)의 이소플라본 유도체를 포함하는 제약학적인 조성물에 관한 것이다. 하기 일반식(Ⅰ)에서, R1은 선택적으로, C1-6알콕시, 히드록실, C1-6카르복시, 페닐, 벤조일 또는 할로 원소로 치환된 C2-18알킬; 선택적으로, 할로 원소 또는 니트로기 또는 C2-6알케닐로 치환된 C1-3알킬 사슬을 포함하는 페닐알킬을 나타내고; R2및 R3은 수소 또는 C1-6알콕시를 나타내고; R4는 수소, C1-6알킬 또는 카르복실을 나타내고; R5는 수소 또는 C1-4알킬을 나타내고; R6는 수소를 나타내거나, R2, R3, R4, R5, 및 R6가 수소를 나타내면, R1이 이소프로필 아니라는 조건하에서, R5가 수소를 나타내면 R6은 메틸 또는 히드록시메틸, 또는 그것의 염을 나타낸다. 공지된 방법으로 제조된 본 발명에 따른 제약학적인 조성물은 골다공증의 치료에 적합하다.The present invention relates to a pharmaceutical composition comprising as an active agent an isoflavone derivative of the general formula (I). In the following general formula (I), R 1 is optionally C 2-18 alkyl substituted with C 1-6 alkoxy, hydroxyl, C 1-6 carboxy, phenyl, benzoyl or halo element; Optionally, phenylalkyl comprising a C 1-3 alkyl chain substituted with a halo element or nitro group or C 2-6 alkenyl; R 2 and R 3 represent hydrogen or C 1-6 alkoxy; R 4 represents hydrogen, C 1-6 alkyl or carboxyl; R 5 represents hydrogen or C 1-4 alkyl; R 6 represents hydrogen or if R 2 , R 3 , R 4 , R 5 , and R 6 represent hydrogen, under the condition that R 1 is not isopropyl, and if R 5 represents hydrogen, R 6 is methyl or hydroxy Methyl, or a salt thereof. Pharmaceutical compositions according to the invention prepared by known methods are suitable for the treatment of osteoporosis.

Description

활성제로서 이소플라본 유도체 또는 그것의 염을 포함하는 제약학적인 조성물-(PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF)PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (3)

적당한 비활성인 고체 또는 액체 담체 및 선택적으로 보통의 치료학적 첨가제 및 보조제를 포함하는 혼합물내에서, 제약학적 활성량의 하기 일반식(Ⅰ)의 화합물을 활성제로서 포함하는 것을 특징으로 하는 골다공증 치료를 위한 제약학적인 조성물:In a mixture comprising a suitable inert solid or liquid carrier and optionally ordinary therapeutic additives and adjuvants, a pharmaceutically active amount of a compound of formula (I) Pharmaceutical Compositions: [상기 일반식(Ⅰ)에서, R1은 선택적으로 C1-6알콕시, 히드록실, C1-6카르복시, 페닐, 벤조일 또는 할로원자로 치환된 C2-18알킬; 선택적으로 할로원자 또는 니트로기 또는 C2-6알케닐로 치환된 C1-3알킬 사슬을 포함하는 페닐알킬을 의미하고; R2및 R3은 수소 또는 C1-6알콕시를 의미하고; R4는 수소, C1-6알킬 또는 카르복실을 의미하고; R5는 수소 또는 C1-4알킬을 의미하고; R6는 수소를 의미하거나, R2, R3, R4, R5및 R6가 수소를 나타내면, R1이 이소프로필 이외의 것을 나타낸다는 조건하에서, R5가 수소를 나타내면, R6은 메틸 또는 히드록시메틸을 의미한다.][In the formula (I), R 1 is C 2-18 alkyl optionally substituted with C 1-6 alkoxy, hydroxyl, C 1-6 carboxy, phenyl, benzoyl or halo atom; Phenylalkyl comprising a C 1-3 alkyl chain optionally substituted with a halo atom or nitro group or C 2-6 alkenyl; R 2 and R 3 mean hydrogen or C 1-6 alkoxy; R 4 means hydrogen, C 1-6 alkyl or carboxyl; R 5 means hydrogen or C 1-4 alkyl; R 6 stands for hydrogen, or, R 2, R 3, R 4, under the condition that indicates other than R 5, and R 6 a represents hydrogen, R 1 is isopropyl, R 5 a represents hydrogen, R 6 is Methyl or hydroxymethyl.] 골다공증의 치료를 위해 제약학적인 조성물을 제조하기 위하여 일반식(Ⅰ)의 화합물(R1, R2, R3, R4및 R5는 제1항에서 정의한 바와 같다.)을 사용하는 방법.A method of using the compounds of formula (I) (R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 ) to prepare a pharmaceutical composition for the treatment of osteoporosis. 적당한 비활성인 고체 또는 액체 담체, 및 선택적으로, 보통의 치료학적 첨가제 및 보조제를 포함하는 혼합물과 함께 유효량의 일반식(Ⅰ)의 화합물(R1, R2, R3, R4및 R5는 제1항에서 정의한 바와 같다.)을 투여하는 단계를 포함하는 골다공증에 걸린 환자 또는 실험용 동물의 골다공증을 치료하는 방법.An effective amount of the compounds of formula (I) (R 1 , R 2 , R 3 , R 4 and R 5 ), in combination with a suitable inert solid or liquid carrier and, optionally, ordinary therapeutic additives and auxiliaries A method of treating osteoporosis in a patient or laboratory animal suffering from osteoporosis comprising the step of administering the same. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960700363A 1993-07-20 1994-07-18 PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF KR960703600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9302082A HUT68396A (en) 1993-07-20 1993-07-20 Method for preparing pharmaceutical preparation containing isoflavone derivative or salt of it
HU2082/93 1993-07-20
PCT/HU1994/000027 WO1995003040A1 (en) 1993-07-20 1994-07-18 Pharmaceutical compositions containing as active agent isoflavone derivatives or salts thereof

Publications (1)

Publication Number Publication Date
KR960703600A true KR960703600A (en) 1996-08-31

Family

ID=10983802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700363A KR960703600A (en) 1993-07-20 1994-07-18 PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF

Country Status (6)

Country Link
EP (1) EP0717621A1 (en)
KR (1) KR960703600A (en)
CN (1) CN1129398A (en)
AU (1) AU7236694A (en)
HU (1) HUT68396A (en)
WO (1) WO1995003040A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289154B1 (en) * 1997-01-03 1998-09-29 Chiesi Farma Spa ISOFLAVONE DERIVATIVES THEIR PREPARATION AND THEIR THERAPEUTIC USE
KR100436220B1 (en) * 2001-08-30 2004-06-12 주식회사 네패스 Organic polymers for bottom antireflective coating, processes for preparing the same, and compositions containing the same
JP2009536610A (en) * 2006-02-28 2009-10-15 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ Pharmaceutical composition for the prevention / treatment of bone disease and preparation method thereof
CN101331913B (en) * 2008-07-22 2011-03-16 广东新南都饲料科技有限公司 Use of isoflavone with substituent at intermedium ring 2 position as animal feed additives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR846M (en) * 1960-01-19 1961-10-02
BE586723A (en) * 1960-01-19 1960-07-19 Sarec S A New chemical and therapeutic compounds derived from isoflavones, and their preparation processes.
US3864362A (en) * 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
HU162377B (en) * 1970-05-27 1973-02-28
US3949085A (en) * 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
AT339130B (en) * 1971-10-20 1977-10-10 Chinoin Gyogyszer Es Vegyeszet WEIGHT INCREASING FEED ADDITIVE
HU166380B (en) * 1973-07-09 1975-03-28
JPS60132917A (en) * 1983-12-21 1985-07-16 Takeda Chem Ind Ltd Remedy for osteoporosis

Also Published As

Publication number Publication date
WO1995003040A1 (en) 1995-02-02
HU9302082D0 (en) 1993-10-28
CN1129398A (en) 1996-08-21
HUT68396A (en) 1995-04-25
AU7236694A (en) 1995-02-20
EP0717621A1 (en) 1996-06-26

Similar Documents

Publication Publication Date Title
KR940014328A (en) Indoline compounds
KR900004333A (en) Angiogenesis inhibitors
KR900018098A (en) Pyridone Carboxylic Acids and Antibacterials
RU94044671A (en) Use of nonpeptide antagonists of tachykinin receptors
KR920008024A (en) Quinoline derivatives
RU94044436A (en) Method of suppression of skin and vagina atrophy
KR870003974A (en) Bicyclo substituted phenylacetonitrile derivatives
KR950010892A (en) How to suppress uterine fibrosis
FR2676444B1 (en) NOVEL AMINO-3 PYRIDAZINE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
KR950016727A (en) How to increase thrombomodulin expression
KR950000663A (en) Triterpene Derivatives and Endothelin-Receptor Antagonists Containing the Same
KR950011445A (en) Galantamine derivatives, preparation method thereof and use thereof as medicament
KR940703655A (en) Pharmaceutical Compositions and Methods of Making the Same
KR900016098A (en) Derivatives of Caffeic Acid and Pharmaceutical Compositions Containing the Same
AU5162396A (en) Protective agent for organ or tissue
KR890014480A (en) 2-pyridylacetic acid derivative, preparation method thereof and pharmaceutical composition containing same
KR900018091A (en) Antispasmodic
KR950702554A (en) 2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents
KR960703600A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE AGENT ISOFLAVONE DERIVATIVES OR SALTS THEREOF
RU94045156A (en) Use of 2-phenyl-3-aroylbenzothiophenes for premature sexual maturation inhibition
KR880012586A (en) New pyridyl and pyrimidyl derivatives
KR870005641A (en) Hypertension Treatment Composition
ATE163850T1 (en) PHARMACEUTICAL COMPOSITIONS OF 5HT1 AGONISTIC ALKYL SULPHONAMIDES FOR RECTAL ADMINISTRATION
RU2223269C2 (en) Derivatives of chroman, intermediate compounds, pharmaceutical composition and method for treatment
KR970701044A (en) Cholinesterase Activator

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid